10-Q: AbbVie Navigates Humira Decline with Strong Growth

AbbVie reports robust revenue growth driven by new immunology and neuroscience drugs, offsetting Humira's biosimilar impact, despite a dip in net earnings due to contingent consideration adjustments.

Summary

• Worldwide net revenues increased by 7.4% to $28.8 billion for the six months ended June 30, 2025, or 8.0% on a constant currency basis, compared to $26.8 billion in the prior year.
• Net earnings attributable to AbbVie Inc. decreased by 18.8% to $2.224 billion for the six months ended June 30, 2025, down from $2.739 billion in the prior year.
• Diluted earnings per share (EPS) attributable to AbbVie Inc. fell by 19.0% to $1.24 for the six months ended June 30, 2025, compared to $1.53 in the prior year.
• Operating earnings increased by 26.9% to $8.6 billion for the six months ended June 30, 2025, up from $6.8 billion in the prior year.
• Cash flows from operations increased by 7.6% to $6.8 billion for the six months ended June 30, 2025, compared to $6.3 billion in the prior year.
• The decrease in net earnings was primarily driven by a significant increase in 'Other expense, net' to $4.08 billion (from $1.93 billion), largely due to a $4.3 billion change in fair value of contingent consideration liabilities.
• Humira net revenues decreased by 54.3% to $2.301 billion for the six months ended June 30, 2025, due to biosimilar competition.
• Skyrizi net revenues surged by 66.2% to $7.848 billion and Rinvoq net revenues increased by 49.3% to $3.746 billion for the six months ended June 30, 2025.
• Acquired Capstan Therapeutics for approximately $2.1 billion upfront cash, adding a Phase 1 anti-CD19 CAR-T therapy candidate for autoimmune diseases.
• Acquired Nimble Therapeutics for $288 million, including an oral peptide IL23R inhibitor for psoriasis in preclinical development.
• Entered a licensing agreement with Ichnos Glenmark Innovation, Inc. for ISB-2001 (multiple myeloma) with a $700 million upfront payment and potential milestones up to $1.2 billion.
• Entered a license option agreement with ADARx Pharmaceuticals, Inc. for siRNA therapeutics with a $335 million upfront payment and potential milestones up to $7.5 billion.
• Completed a licensing agreement with Gubra A/S for GUB014295 (obesity) with a $350 million upfront payment and potential milestones up to $1.9 billion.
• Received US FDA accelerated approval for Emrelis for non-squamous non-small cell lung cancer and US FDA approval for Emblaveo for complicated intra-abdominal infections.
• US Tax Court granted summary judgment in AbbVie's favor regarding a $572 million income tax benefit dispute from 2014.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While net earnings and EPS declined due to a specific accounting adjustment (contingent consideration fair value change), the underlying operational performance is strong with robust revenue growth from key products, increased operating earnings, and healthy cash flow. The company is effectively managing the Humira biosimilar impact and actively expanding its pipeline through strategic acquisitions and licensing. Legal wins also contribute positively. The non-cash nature of the primary earnings drag and its link to higher future sales estimates for growth products suggest a fundamentally sound business.

Positives

• Worldwide net revenues grew by 7.4% reported and 8.0% at constant currency, demonstrating strong underlying business performance.
• Operating earnings increased significantly by 26.9% to $8.6 billion, indicating improved operational efficiency and profitability before non-operating items.
• Cash flows from operations increased by 7.6% to $6.8 billion, providing strong liquidity for investments and shareholder returns.
• Immunology portfolio continues to drive growth, with Skyrizi revenues up 66.2% to $7.848 billion and Rinvoq revenues up 49.3% to $3.746 billion.
• Neuroscience products showed strong performance, including Vraylar up 13.5%, Botox Therapeutic up 15.5%, Ubrelvy up 33.4%, and Qulipta up 63.6%.
• Oncology portfolio saw significant growth from Elahere (up 75.5% to $338 million) and Epkinly (up 93.3% to $121 million).
• Strategic acquisitions and licensing agreements (Capstan, Nimble, Ichnos Glenmark, ADARx, Gubra) are expanding the pipeline into new therapeutic areas like obesity and strengthening existing ones.
• Multiple regulatory approvals and positive clinical trial results for key pipeline assets, including Rinvoq for GCA, Emrelis for NSCLC, Emblaveo for infections, and Mavyret label expansion.
• Favorable legal outcomes, including a summary judgment win in the US Tax Court for a $572 million income tax benefit and summary judgment granted in the Holwill federal securities lawsuit.
• Gross margin as a percentage of net revenues increased to 71% from 69%, reflecting increased leverage from revenue growth and lower amortization of intangibles.
• Increased quarterly cash dividend to $1.64 per share, demonstrating commitment to shareholder returns.
• Remaining stock repurchase authorization of approximately $2.9 billion provides flexibility for future share buybacks.

Negatives

• Net earnings attributable to AbbVie Inc. decreased by 18.8% to $2.224 billion, and diluted EPS decreased by 19.0% to $1.24, primarily due to non-cash accounting adjustments.
• Humira net revenues declined significantly by 54.3% to $2.301 billion due to continued direct biosimilar competition.
• Botox Cosmetic net revenues decreased by 7.6% to $1.248 billion, and Juvederm Collection net revenues decreased by 22.2% to $491 million, driven by lower market share, decreased consumer demand, and unfavorable pricing in the US.
• Imbruvica global revenues decreased by 10.7% to $1.492 billion due to decreased demand and unfavorable pricing in the United States, as well as decreased collaboration revenues.
• Linzess/Constella net revenues decreased by 16.4% to $406 million.
• Venclexta's global Phase 3 VERONA trial for myelodysplastic syndrome did not meet its primary endpoint of overall survival.
• Interest expense, net, increased by 36.1% to $1.305 billion due to a higher average debt balance.
• Other expense, net, more than doubled to $4.08 billion, primarily due to a $4.3 billion increase in the fair value of contingent consideration liabilities, which negatively impacted net earnings.

Risks

• Challenges to intellectual property rights could impact product exclusivity and revenue streams.
• Competition from other products, including biosimilars for key drugs like Humira, continues to exert pressure on market share and pricing.
• Difficulties inherent in the research and development process, including clinical trial failures or regulatory setbacks, could delay or prevent new product launches.
• Adverse litigation or government action, such as ongoing antitrust lawsuits, opioid litigation, or product liability claims, could result in significant financial penalties or operational restrictions.
• Changes to laws and regulations applicable to the pharmaceutical industry, including those related to drug pricing (e.g., Executive Order 14297 on most-favored-nation pricing), could adversely impact profitability.
• Impact of global macroeconomic factors, such as economic downturns, international conflicts, trade disputes, and tariffs, may increase uncertainties and adversely affect business operations.
• The 'One Big Beautiful Bill Act of 2025' introduces new tax provisions and healthcare regulations that AbbVie is currently evaluating for potential impact on financial statements.

Future Outlook

The company anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months. Multiple mid-stage programs are expected to transition into late-stage programs within the next 12 months. The company is currently evaluating the potential impact of the 'One Big Beautiful Bill Act of 2025' on its consolidated financial statements, which includes new tax provisions and healthcare provisions. The company intends to fund short-term and long-term financial obligations through cash on hand, future cash flows from operations, or by issuing additional debt, and believes it has sufficient financial flexibility to support its growth objectives.

Management Comments

• AbbVie's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution.
• The company intends to execute its strategy by maximizing the benefits of a diversified revenue base with multiple long-term growth drivers.
• Management aims to leverage commercial strength and international infrastructure across therapeutic areas and ensure strong commercial execution of new product launches.
• The company will continue to invest in and expand its pipeline in support of opportunities in immunology, neuroscience, oncology, aesthetics, and eye care, as well as continued investment in key on-market products.
• Management expects to generate substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.

Industry Context

The biopharmaceutical industry is characterized by intense competition, high R&D costs, and significant regulatory scrutiny. AbbVie's strategy of diversifying its revenue base and aggressively investing in its pipeline through acquisitions and licensing agreements is a common industry trend to mitigate risks associated with patent expirations and biosimilar competition, as seen with Humira. The focus on immunology, neuroscience, and oncology aligns with high-growth therapeutic areas with significant unmet medical needs. The entry into the obesity market reflects a strategic move into a rapidly expanding and lucrative therapeutic area. The increasing pressure on pharmaceutical pricing, exemplified by Executive Order 14297, indicates a challenging regulatory environment that could impact future revenue and profitability across the industry.

Comparison to Industry Standards

• AbbVie's revenue growth of 7.4% (8.0% constant currency) is strong, especially considering the significant decline of Humira. This compares favorably to peers facing patent cliffs, demonstrating successful diversification and new product uptake.
• The growth rates of Skyrizi (+66.2%) and Rinvoq (+49.3%) are indicative of best-in-class performance for new immunology launches, outperforming many new drug introductions by competitors like Johnson & Johnson's Tremfya or Eli Lilly's Taltz in their early growth phases.
• The decline in Humira (-54.3%) is a direct consequence of biosimilar entry, a challenge faced by all blockbuster drugs post-exclusivity. AbbVie's ability to maintain overall revenue growth despite this significant headwind positions it better than companies that have historically struggled to replace lost revenue from patent expirations.
• The substantial increase in 'Other expense, net' due to contingent consideration liabilities, while impacting GAAP net earnings, is a common accounting feature for companies engaged in significant M&A, particularly in biotech. This increase is tied to higher estimated future sales of acquired products (like Skyrizi), which is a positive indicator of the acquired assets' value, unlike a pure operational loss.
• The failure of the Venclexta Phase 3 VERONA trial for myelodysplastic syndrome is a setback, but clinical trial failures are inherent risks in pharmaceutical R&D and are not uncommon across the industry. Companies like Pfizer or Merck also experience such outcomes in their extensive pipelines.
• AbbVie's active M&A and licensing strategy, including the acquisition of Capstan Therapeutics and licensing deals with Ichnos Glenmark and ADARx, is consistent with industry leaders like Bristol Myers Squibb or Gilead Sciences, who frequently use external innovation to bolster their pipelines and expand into new therapeutic modalities (e.g., CAR-T, siRNA).

Management Changes

Corporate Governance

Legal Proceedings

• Antitrust Litigation (In re: Niaspan Antitrust Litigation, MDL No. 2460) is pending against AbbVie and others, alleging violations of antitrust laws related to a 2005 patent litigation settlement.
• Government Proceedings (In re: National Prescription Opiate Litigation, MDL No. 2804) involve approximately 380 lawsuits against Allergan (an AbbVie entity) regarding the promotion and sale of prescription opioid products, with some cases in the process of dismissal due to settlement.
• A US Tax Court petition (AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue) disputing a $572 million income tax benefit from 2014 was resolved in AbbVie's favor via summary judgment in June 2025.
• A putative class action lawsuit (Reese v. AbbVie Inc.) challenging a by-law provision was voluntarily dismissed as moot in September 2024, with a $175 thousand payment to plaintiff's counsel.
• A federal securities lawsuit (Holwill v. AbbVie Inc., et al.) alleging misleading statements about Humira sales growth was granted summary judgment in favor of AbbVie and individual defendants in July 2025.
• A putative class action lawsuit (Camargo v. AbbVie Inc.) is pending on behalf of Humira patients, alleging excessive list prices in violation of unfair and deceptive trade practices statutes.
• Product Liability and General Litigation (In re: Allergan Biocell Textured Breast Implant Product Liability Litigation, MDL No. 2921) involves approximately 145 ALCL lawsuits and 1,290 other lawsuits against Allergan entities globally, related to textured breast implants.
• A putative class action lawsuit (Sheet Metal Workers Health Plan of Southern California, Arizona, and Nevada v. AbbVie Inc.) is pending, alleging AbbVie's rebating practices impair biosimilar competition with Humira.
• Intellectual Property Litigation is ongoing to enforce patent rights for upadacitinib (Rinvoq) and ubrogepant (Ubrelvy) against proposed generic products.

Related Party Transactions

• Collaboration with Janssen Biotech, Inc. for Imbruvica: AbbVie and Janssen share pre-tax profits and losses equally from commercialization. Janssen's share of US profits ($253 million for Q2 2025, $500 million for H1 2025) is included in cost of products sold. AbbVie's share of international profits ($211 million for Q2 2025, $420 million for H1 2025) is included in net revenues. AbbVie's share of other costs ($25 million for Q2 2025, $50 million for H1 2025) is included in respective line items.
• Collaboration with Genentech, Inc. for Venclexta: AbbVie shares equally with Genentech all pre-tax profits and losses from US development and commercialization. Genentech's share of profits, including royalties ($262 million for Q2 2025, $504 million for H1 2025), is included in cost of products sold. AbbVie's share of sales and marketing costs ($3 million for Q2 2025, $13 million for H1 2025) and development costs ($15 million for Q2 2025, $32 million for H1 2025) are reported net of Genentech's share.

Stakeholder Impact

• Shareholders: Impacted by decreased net earnings and EPS, but also by increased operating earnings, strong revenue growth from new products, increased dividends, and ongoing share repurchase program. Favorable legal outcomes reduce potential liabilities.
• Employees: Restructuring plans are ongoing to optimize operations, which may affect employees. Acquisitions and pipeline expansion could create new opportunities.
• Customers (Wholesalers, Distributors, Healthcare Facilities, Physicians, Patients): Benefit from new product approvals (Emrelis, Mavyret label expansion) and expanded indications for existing drugs (Rinvoq, Qulipta). Patients using Humira face biosimilar competition, potentially leading to lower costs.
• Suppliers: Ongoing operations and R&D investments suggest continued demand for supplies and services.
• Creditors: The company issued $4.0 billion in new senior notes and utilized term loans, increasing debt. However, strong operating cash flows and revolving credit facilities indicate robust liquidity and ability to meet obligations. Credit ratings remained unchanged.

Next Steps

• Close the proposed acquisition of Capstan Therapeutics, Inc. in 2025, subject to regulatory approvals and customary closing conditions.
• Close the licensing agreement with Ichnos Glenmark Innovation, Inc. in 2025, subject to regulatory approvals and customary closing conditions.
• Continue to evaluate the impact of the 'One Big Beautiful Bill Act of 2025' on consolidated financial statements.
• Anticipate several regulatory submissions and data readouts from key clinical trials in the next 12 months.
• Expect multiple mid-stage programs to transition into late-stage programs in the next 12 months.
• Continue to assess the impact of adopting new accounting standards ASU No. 2024-03 (effective 2027/2028) and ASU No. 2023-09 (effective 2025) on consolidated financial statements.
• Continue to monitor and manage exposures to global macroeconomic conditions, including international trade disruptions and pharmaceutical pricing pressures.

Key Dates

Recommendation

Despite a reported decline in net earnings, the underlying operational performance is strong, with robust revenue growth driven by key immunology and neuroscience assets that are successfully offsetting the expected decline of Humira. The decrease in net earnings is primarily due to a non-cash accounting adjustment related to contingent consideration, which itself reflects higher estimated future sales of acquired growth products. Operating earnings and cash flow from operations are both up, indicating healthy core business fundamentals. The company's aggressive pipeline expansion through strategic acquisitions and licensing, coupled with recent regulatory approvals and favorable legal outcomes, positions it well for sustained long-term growth. The increased dividend and ongoing share repurchase program demonstrate management's confidence and commitment to shareholder returns. This filing suggests a company effectively executing its strategy and building a diversified, high-growth portfolio.

Keywords

Biopharmaceutical, Immunology, Neuroscience, Oncology, Aesthetics, Eye Care, Drug Development, SEC Filing, Quarterly Report, Pharmaceuticals, Humira, Skyrizi, Rinvoq, Vraylar, Botox, Acquisitions, Pipeline, Clinical Trials, Financial Results, EPS, Revenue, Cash Flow, Contingent Consideration, Intellectual Property, Litigation, Capital Allocation